- Home
- BRNS vs CRIS Comparison
BRNS vs CRIS Comparison
Compare BRNS & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- CRIS
- Stock Information
- Founded
- BRNS 2016
- CRIS 2000
- Country
- BRNS United Kingdom
- CRIS United States
- Employees
- BRNS N/A
- CRIS N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRNS Health Care
- CRIS Health Care
- Exchange
- BRNS Nasdaq
- CRIS Nasdaq
- Market Cap
- BRNS 36.7M
- CRIS 31.2M
- IPO Year
- BRNS 2021
- CRIS 2000
- Fundamental
- Price
- BRNS $1.17
- CRIS $3.45
- Analyst Decision
- BRNS Strong Buy
- CRIS Strong Buy
- Analyst Count
- BRNS 2
- CRIS 3
- Target Price
- BRNS $4.00
- CRIS $23.00
- AVG Volume (30 Days)
- BRNS 69.8K
- CRIS 66.1K
- Earning Date
- BRNS 11-06-2024
- CRIS 02-06-2025
- Dividend Yield
- BRNS N/A
- CRIS N/A
- EPS Growth
- BRNS N/A
- CRIS N/A
- EPS
- BRNS N/A
- CRIS N/A
- Revenue
- BRNS $14,969,000.00
- CRIS $10,259,000.00
- Revenue This Year
- BRNS $1,805.74
- CRIS N/A
- Revenue Next Year
- BRNS N/A
- CRIS N/A
- P/E Ratio
- BRNS N/A
- CRIS N/A
- Revenue Growth
- BRNS 106.21
- CRIS 0.44
- 52 Week Low
- BRNS $0.80
- CRIS $3.43
- 52 Week High
- BRNS $4.16
- CRIS $17.49
- Technical
- Relative Strength Index (RSI)
- BRNS 57.61
- CRIS 38.10
- Support Level
- BRNS $0.80
- CRIS $3.42
- Resistance Level
- BRNS $1.05
- CRIS $4.25
- Average True Range (ATR)
- BRNS 0.12
- CRIS 0.31
- MACD
- BRNS 0.03
- CRIS -0.03
- Stochastic Oscillator
- BRNS 100.00
- CRIS 13.83
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.